Secondary Carcinoma — Trials

Secondary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

222 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 75
Recruiting: 42
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: Guangzhou Medical University
Termination share: 26%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06462222	Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors	active not recruiting	Phase 1 / Phase 2	45	Guangzhou Medical UniversityOTHER	1	Sep 24, 2026	clinicaltrials
NCT06762080	Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis	active not recruiting	Phase 1 / Phase 2	36	Guangzhou Medical UniversityOTHER	1